The basis for HIV immunotherapeutic vaccines (Q34460375)

2 August 2017

1 reference

title

The basis for HIV immunotherapeutic vaccines (English)

1 reference

2 August 2017

1 reference

Peters BS

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

20

1 reference

2 August 2017

issue

5-6

1 reference

2 August 2017

page(s)

688-705

1 reference

HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Studies in subjects with long-term nonprogressive human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Enhancement of HIV Type 1 Antigen-Specific CD4 T Cell Memory in Subjects with Chronic HIV Type 1 Infection Receiving an HIV Type 1 Immunogen.

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Highly active antiretroviral therapy normalizes the potential for MIP-1alpha production in HIV infection

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Induction of specific T-cell responses in HIV infection

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Enhancement of human immunodeficiency virus (HIV)-specific CD4 and CD8 cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Induction of CD4 human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Active Immunization of Patients with HIV Infection: A Study of the Effect of VaxSyn, a Recombinant HIV Envelope Subunit Vaccine, on Progression of Immunodeficiency

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV inf

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

CD8 lymphocyte antiviral activity in monkeys immunized with SIV recombinant poxvirus vaccines: potential role in vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Viremia control following antiretroviral treatment and therapeutic immunizationduring primary SIV251 infection of macaques

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Immune control of HIV-1 after early treatment of acute infection

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Control of SIV rebound through structured treatment interruptions during early infection

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

A therapeutic HIV vaccine using coxsackie-HIV recombinants: a possible new strategy

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Induction of HIV-1-specific T-helper responses and type 1 cytokine secretion following therapeutic vaccination of macaques with a recombinant fowlpoxvirus co-expressing interferon-gamma

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

HIV infection and pathogenesis: what about chemokines?

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1.

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS.

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Human immunodeficiency virus tat gene transfer to the murine central nervous system using a replication-defective herpes simplex virus vector stimulates transforming growth factor beta 1 gene expression

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

The Human Immunodeficiency Virus Type 1 Tat Protein Potentiates Zidovudine-Induced Cellular Toxicity In Transgenic Mice

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoid

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Genetic immunization is a simple method for eliciting an immune response

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Heterologous protection against influenza by injection of DNA encoding a viral protein

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

DNA inoculation induces cross clade anti-HIV-1 responses

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

In vivo protective anti-HIV immune responses in non-human primates through DNA immunization.

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

DNA Vaccination as Anti—Human Immunodeficiency Virus Immunotherapy in Infected Chimpanzees

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

An anti-HIV strategy combining chemotherapy and therapeutic vaccination

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Humoral and cellular immune responses to HIV-1 Nef in mice DNA-immunised with non-replicating or self-replicating expression vectors

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Macrophage inflammatory protein-1alpha (MIP-1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Immunogenicity of a novel DNA vaccine cassette expressing multiple human immunodeficiency virus (HIV-1) accessory genes

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids.

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Anti-major histocompatibility complex antibody responses in macaques via intradermal DNA immunizations

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Cationic microparticles: A potent delivery system for DNA vaccines

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-gamma, IL-12, or IL-18 gene adjuvants

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Immunization against SIVmne in macaques using multigenic DNA vaccines

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4 cell numbers and clinical staging

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Acquisition of host cell-surface-derived molecules by HIV-1.

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Does the HIV envelope induce a chronic graft-versus-host-like disease?

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Anti-cell antibody in macaques

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

The ability of certain SIV vaccines to provoke reactions against normal cells

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Semiallogeneic cell hybrids as therapeutic vaccines for cancer

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Alloimmunization as a strategy for vaccine design against HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Up-regulation of beta-chemokines and down-modulation of CCR5 co-receptors inhibit simian immunodeficiency virus transmission in non-human primates

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Heat shock proteins generate beta-chemokines which function as innate adjuvants enhancing adaptive immunity

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Heat shock protein-based therapeutic strategies against human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Induction of inhibitory antibodies to the CCR5 chemokine receptor and their complementary role in preventing SIV infection in macaques

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

gammadelta T cells regulate mucosally induced tolerance in a dose-dependent fashion

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Mechanisms of MHC class I--restricted antigen processing

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Therapeutic potential of blocking HIV entry into cells: focus on membrane fusion inhibitors

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Inhibition of infection of incoming HIV-1 virus by RNA-cleaving DNA enzyme

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Antisense RNA sequences targeting the 5' leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Inhibition of human immunodeficiency virus type 1 replication by nuclear chimeric anti-HIV ribozymes in a human T lymphoblastoid cell line

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Transient protection of human T-cells from human immunodeficiency virus type 1 infection by transduction with adeno-associated viral vectors which express RNA decoys

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

RNA-based gene therapy for HIV infection

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120.

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

Simian immunodeficiency virus DNA vaccine trial in macaques.

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(01)00394-2

7 January 2021

10.1016/S0264-410X(01)00394-2

Identifiers

DOI

1 reference

2 August 2017

1 reference